本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Cartesian Therapeutics

15.80
-0.8100-4.88%
盤後15.800.00000.00%17:24 EDT
成交量:19.82萬
成交額:321.24萬
市值:4.06億
市盈率:-0.68
高:16.75
開:16.58
低:15.80
收:16.61
資料載入中...

公司資料

公司名字:
Cartesian Therapeutics
交易所:
NASDAQ
成立時間:
- -
員工人數:
38
公司地址:
704 Quince Orchard Road,Gaithersburg,Maryland,United States
郵編:
20878
電話:
傳真:
- -
簡介:
Cartesian Therapeutics, Inc.在特拉華州成立。該公司是一家臨床階段的公司,開創了治療自身免疫性疾病的RNA細胞療法。該公司的主要資產Descartes-08是一種潛在的first-in-class、RNA工程嵌合抗原受體T細胞療法(rCAR-T),正處於全身性重症肌無力患者的2b期臨床開發階段,並計劃在系統性紅斑狼瘡以及眼部自身免疫和血管性自身免疫籃子試驗中開展額外的2期研究。Cartesian在馬里蘭州蓋瑟斯堡經營一家全資擁有的最先進的cGMP生產設施。

董事

名稱
職位
Carrie S. Cox
Chairman of the Board,Director
Carsten Brunn
President and Chief Executive Officer,Director
Aymeric Sallin
Director
Goran Ando
Director
Patrick Zenner
Director
Scott D. Myers
Director
Timothy A. Springer
Director
Timothy C. Barabe
Director

股東

名稱
職位
Carsten Brunn
President and Chief Executive Officer,Director
Lloyd Johnston
Chief Operating Officer and Senior Vice President, Research and Development
Bradford D. Dahms
Chief Financial Officer
Elona Kogan
General Counsel and Secretary
Stephen Smolinski
Chief Commercial Officer
Takashi Kei Kishimoto
Chief Scientific Officer